Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_2
2
67%
Ph phase_3
1
33%

Phase Distribution

0

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Other(3)

Detailed Status

unknown3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 22 (66.7%)
Phase 31 (33.3%)

Trials by Status

unknown3100%

Recent Activity

0 active trials
Showing 3 of 3
unknownphase_2

PEG-ASP, Etoposide and Gemcitabine for Natural Killer/T Lymphoma

NCT02705508
unknownphase_2

Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian Cancer

NCT03618706
unknownphase_3

Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy for Recurrent Advanced Follicular Lymphoma

NCT02438501

Clinical Trials (3)

Showing 3 of 3 trials
NCT02705508Phase 2

PEG-ASP, Etoposide and Gemcitabine for Natural Killer/T Lymphoma

Unknown
NCT03618706Phase 2

Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian Cancer

Unknown
NCT02438501Phase 3

Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy for Recurrent Advanced Follicular Lymphoma

Unknown

All 3 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
3